Where CRC were linked to somatic BRAF mutation, the risk was associated with long-term smoking [18].
For example, these annotations may describe the country of origin, the presence of a given resistance mutation, the risk group, the mode of transmission and so forth.
In breast cancer kindreds without a demonstrable BRCA mutation, the risk for breast cancer in female first degree relatives was about twice the risk in the general population.
Among women with a BRCA1 mutation, the risk of breast cancer increased by 1.2-fold for each first-degree relative with breast cancer before age 50 years (HR=1.21; 95% CI 0.94 1.57), and among women with a BRCA2 mutation, the risk of breast cancer increased by 1.7-fold for each first-degree relative with breast cancer (HR=1.65; 95% CI 1.00 2.71).
In genotype C virus infected patients, the BCP mutation is reported to accumulate as aging and associated with an increased risk of HCC, however, when the BCP mutation coexisted with precore mutation, the risk of HCC have decreased [ 33, 34].
These curves indicate that in individuals carrying the NAT1 mutation, the risk of asthma increases approximately 2-fold or more in 20% of the possible polygenotypes present in a population of workers exposed to diisocyanates.
However, in women who carry a BRCA mutation, the risk of a recurrence or a new primary in the ipsilateral breast at 10 years is estimated to be as high as 20%to50%0% [ 12].
In women with BRCA1 or 2 gene mutations, the risks of pregnancy are not well established.
The BOADICEA model can be used to estimate the likelihood of carrying a BRCA1 or a BRCA2 mutation, and the risks of developing breast or ovarian cancer.
While much is known about the three common Ashkenazi BRCA1 and BRCA2 mutations, the risk they confer varies.
